NCT Number: NCT02424578
Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age
The purposes of this study are to evaluate the safety and tolerability and to model the single-dose pharmacokinetic profile of diclofenac capsules low dose and high dose in children ages 6 to <17 years experiencing mild to moderate acute postoperative pain.
Looking for future studies?
Notify MeKey information
Conditions
Age range
6 year–16 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Sheffield, Alabama, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Body weight ≥18 kilograms.
- Mild to moderate acute pain requiring treatment with analgesic medication.
- Willing to have blood samples taken for PK sampling using an indwelling catheter.
- Must be able to swallow capsules and can tolerate oral medication.
- For females: is not of reproductive potential (defined as premenarchal) or is practicing an acceptable method of birth control
Exclusion criteria
- Severe acute pain
- Chronic analgesic or glucocorticoid use for any condition within 6 months before dosing with study drug.
- Emergency surgery
- History of allergic reaction, hypersensitivity, or clinically significant intolerance to diclofenac, aspirin, codeine, acetaminophen, or any NSAID
- History of peptic ulcer disease or a GI event (eg, perforation, obstruction, or bleed) within 6 months before screening
- Current use of any medication that may cause a clinically significant drug interaction when co-administered with diclofenac
- Current use of any medication that might affect the pharmacokinetics of diclofenac
- History of bleeding disorders .
- Developmental delay or behavioral problems that would make it difficult to assess pain.
- Impaired liver function
- Clinically significant renal or cardiovascular disease
- Any medical condition that compromises ability to swallow, absorb, metabolize, or excrete the study drug
- Previously received any investigational product or device within 30 days before Screening or scheduled to receive an investigational device or another investigational drug (other than that in this study) during the course of this study.
- Previous participation in this clinical study or currently taking diclofenac.
Treatment and study plan
Diclofenac Capsules high dose
DrugPrimary outcomes
-
Plasma Concentration of Diclofenac
Time frame: 0-6 hours after first dose of diclofenac
The estimated typical value for clearance (tvCl) following a single diclofenac dose based on population pharmacokinetic (PopPK) modeling using sparse plasma concentration data in pediatric subjects.
Secondary outcomes
-
Safety of Diclofenac Capsules Low Dose and High Dose as Assessed by the Incidence of Adverse Events From Baseline to Day 3 or Early Termination
Time frame: Baseline to Day 3/Early Termination
Sponsors and collaborators
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Registry information
Official study title
A Phase IIA, Open-Label, Safety and Pharmacokinetic Study of Diclofenac Capsules in Pediatric Subjects 6 to <17 Years of Age With Mild to Moderate Acute Postoperative Pain Following Elective Surgery
Important dates
- Study start
- 2015
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Apr 23, 2015
- Registry last updated
- Jul 13, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement
NCT05283980
Acute Pain, Behavior
Boston, Massachusetts, United States
View Trial DetailsCryoanalgesia Study
NCT05859061
Neurologic Manifestations, Pain
Chicago, Illinois, United States
View Trial DetailsBridging the Healing Gap: A Single-Blind Clinical Trial Assessing the Efficacy of Carboxy-gel in Reducing Bruising and Pain Post-Liposuction
NCT06791577
Blood Coagulation Disorders, Bruising
São Paulo, Brazil
View Trial DetailsPrevention of Post Mastectomy With Intraoperative Ketamine
NCT03090776
Neurologic Manifestations, Pain
Boston, Massachusetts, United States
View Trial Details